Information  X 
Enter a valid email address

Elsevier (REL)

  Print      Mail a friend       Annual reports

Monday 29 June, 2009

Elsevier

Elsevier Announces 2008 Journal Impact Factor H...





AMSTERDAM, June 29 /PRNewswire/ --

    - 51 Elsevier Journals Receive Top Rank and Show Continued Focus
on Quality



    Elsevier, the leading publisher of scientific, technical and medical
information products and services, today announced the highlights of its
journal impact factor performance in 2008. Elsevier overall saw 75% of its
journal impact factors (IF) increase from 2007 to 2008. According to the 2008
Journal Citation Report(R) published by ThomsonReuters, Elsevier journals
took the #1 position in 51 categories (of 229 in total) across all of the
sciences and social sciences.



    In addition, 30 Elsevier journals got their first IF this year. Some of
these journals received very impressive scores including two Cell Press
journals: Cell Stem Cell (http://www.cell.com/cell-stem-cell/home) (16.826)
entered the Cell Biology category ranked 6th (of 157 journals), while Cell
Host & Microbe (http://www.cell.com/cell-host-microbe/home) (7.436) entered
the Microbiology category ranked10th (of 91 journals). Another impressive
result in its first year is Materials Today (http://www.materialstoday.com/)
(12.929), which is ranked 4th in the Materials Science, Multidisciplinary
category (of 191 journals).



    This year there were 182 Elsevier journals that increased their IF by
more than 50% over their 2007 scores. All three The Lancet speciality
journals improved their IF this year. The Lancet Infectious Diseases
(http://www.thelancet.com/journals/laninf/issue/current) increased to 13.165,
placing it at the #1 position in the Infectious Diseases category. The Lancet
Oncology (http://www.thelancet.com/journals/lanonc/issue/current) rose to
13.283, an increase of over 1 full IF point from the 2007 IF. Finally, The
Lancet Neurology (http://www.thelancet.com/journals/laneur/issue/current)
increased by 40% to 14.270, thereby retaining the #1 position in the Clinical
Neurology category for the 5th year running.



    Other Elsevier journals continue their long-running trend of increased
IFs, in particular Biomaterials (http://www.elsevier.com/locate/biomaterials)
(increasing yearly since 2003) and The Journal of Allergy and Clinical
Immunology (http://www.elsevier.com/locate/jaci) which has shown consistent
growth over the past five years.



    Glen Campbell, Senior Vice President of U.S. Health Sciences Journals
said, "Each annual announcement of impact factors confirms the depth and
excellence of our health sciences journal publishing program. The superior
performance of so many of our journals this year is a sign of the strong
partnerships we have with our journal editors and our societies. This year's
impact factor growth is one indication of the hard work and focus on quality
of these collaborations."



    "The fact that Elsevier's overall results are amongst the best in the
industry is a true indication of the impact of the increased focus on quality
we have placed on our journals in the past three years. The increased impact
factors, across the board, are evidence that the research we publish is of
the highest quality," remarked Martin Tanke, Managing Director of Science and
Technology Journals. "We are grateful for our strong network of editors we
partner with, who work with us each day to build our journals to some of the
best in their fields."



    The impact factor is a measure of the frequency with which the average
article in a journal has been cited in a particular year. The impact factor
helps to evaluate a journal's relative importance, especially when compared
with others in the same field.



About Elsevier

    Elsevier is a world-leading publisher of scientific, technical and 
medical information products and services. Working in partnership with the 
global science and health communities, Elsevier's 7,000 employees in over 70 
offices worldwide publish more than 2,000 journals and 1,900 new books per 
year, in addition to offering a suite of innovative electronic products, such 
as ScienceDirect (http://www.sciencedirect.com/), MD Consult (
http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),
bibliographic databases, and online reference works.



    Elsevier (http://www.elsevier.com/) is a global business headquartered in
Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of
Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading
publisher and information provider. Operating in the science and medical,
legal, education and business-to-business sectors, Reed Elsevier provides
high-quality and flexible information solutions to users, with increasing
emphasis on the Internet as a means of delivery. Reed Elsevier's ticker
symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange).



    
    Contact:

    Shira Tabachnikoff
    Phone +31-20-485-2736
    E-mail [email protected]

a d v e r t i s e m e n t